慢性乙型肝炎的一线治疗选择精选.pptVIP

* * * * * * * * * 替比夫定 might be used in patients with good predictors of response （HBVDNA2×106 IU/ml, i.e. approximately 107 copies/ml, or 6.3 log10 IU/ml at baseline） with verification of HBVDNA suppression below detection in real-time PCR assay at 24 weeks. * * * * * * 16 HBeAg-positive patients were eligible to be switched to open label TDF/FTC * * * * Inference: Qualitative scientific relationships between antiviral effect and other efficacy parameters likely to be similar for all direct-acting Antivirals (e.g., all polymerase inhibitors) * * * * * * * NUC长期治疗 适应证： 未发生HBe血清转换的HBeAg阳性患者